Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hernan Cortes

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Oncology|April 18, 2012
First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA studyChristoph Thomssen, Jean-Yves Pierga, Kathleen I Pritchard, et al.
European Journal of Cancer (Oxford, England : 1990)|December 27, 2011
Safety of bevacizumab in metastatic breast cancer patients undergoing surgeryJavier Cortés, Mireia Caralt, Suzette Delaloge, et al.
Breast Cancer Research and Treatment|August 11, 2011
Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trialIan Smith, Jean-Yves Pierga, Laura Biganzoli, et al.
Breast (Edinburgh, Scotland)|July 23, 2014
A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trialAntonio Llombart-Cussac, Xavier Pivot, Laura Biganzoli, et al.
Journal of Blood Medicine|May 24, 2014
Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experienceAnalia Rodriguez Garzotto, Susana Cortijo Casacajares, Cristina Pernaut, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancerGunnar Folprecht, Josep Tabernero, Claus-Henning Köhne, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2015
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancerAmir Sonnenblick, Prudence A Francis, Hatem A Azim, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Oncology|April 18, 2012
First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA studyChristoph Thomssen, Jean-Yves Pierga, Kathleen I Pritchard, et al.
European Journal of Cancer (Oxford, England : 1990)|December 27, 2011
Safety of bevacizumab in metastatic breast cancer patients undergoing surgeryJavier Cortés, Mireia Caralt, Suzette Delaloge, et al.
Breast Cancer Research and Treatment|August 11, 2011
Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trialIan Smith, Jean-Yves Pierga, Laura Biganzoli, et al.
Breast (Edinburgh, Scotland)|July 23, 2014
A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trialAntonio Llombart-Cussac, Xavier Pivot, Laura Biganzoli, et al.
Journal of Blood Medicine|May 24, 2014
Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experienceAnalia Rodriguez Garzotto, Susana Cortijo Casacajares, Cristina Pernaut, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancerGunnar Folprecht, Josep Tabernero, Claus-Henning Köhne, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2015
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancerAmir Sonnenblick, Prudence A Francis, Hatem A Azim, et al.
Pageof 3